Guardant Health (NASDAQ:GH) CEO Amirali Talasaz Sells 37,500 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz sold 37,500 shares of Guardant Health stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $169.16, for a total value of $6,343,500.00. Following the transaction, the chief executive officer directly owned 37,500 shares in the company, valued at approximately $6,343,500. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Amirali Talasaz also recently made the following trade(s):

• On Friday, June 26th, Amirali Talasaz sold 116,972 shares of Guardant Health stock. The stock was sold at an average price of $150.79, for a total transaction of $17,638,207.88.
• On Monday, June 29th, Amirali Talasaz sold 143,028 shares of Guardant Health stock. The shares were sold at an average price of $151.54, for a total transaction of $21,674,463.12.

Guardant Health Stock Performance

Shares of GH traded down $7.51 during mid-day trading on Monday, reaching $163.18. The stock had a trading volume of 2,211,234 shares, compared to its average volume of 2,311,072. The business has a fifty day moving average of $153.91 and a 200 day moving average of $118.72. The firm has a market cap of $21.90 billion, a price-to-earnings ratio of -46.76 and a beta of 1.60. Guardant Health, Inc. has a 12 month low of $53.40 and a 12 month high of $176.58.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.34. The firm had revenue of $334.98 million for the quarter, compared to the consensus estimate of $314.23 million. The firm’s revenue for the quarter was up 44.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.44) earnings per share. On average, research analysts forecast that Guardant Health, Inc. will post -2.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Guardant Health

Large investors have recently bought and sold shares of the business. AQR Capital Management LLC grew its stake in shares of Guardant Health by 56.5% in the 1st quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock worth $3,012,000 after buying an additional 25,831 shares in the last quarter. Empowered Funds LLC bought a new position in shares of Guardant Health in the 1st quarter valued at about $274,000. Sei Investments Co. grew its position in Guardant Health by 15.8% in the second quarter. Sei Investments Co. now owns 77,308 shares of the company’s stock worth $4,023,000 after acquiring an additional 10,538 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Guardant Health by 9.4% during the second quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock worth $32,922,000 after acquiring an additional 54,284 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Guardant Health by 56.4% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock worth $5,800,000 after acquiring an additional 40,209 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on GH shares. Citigroup increased their target price on Guardant Health from $150.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Guggenheim upped their price target on Guardant Health from $160.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Evercore reaffirmed an “outperform” rating and set a $200.00 price objective on shares of Guardant Health in a report on Monday, July 6th. Bank of America boosted their target price on shares of Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a report on Monday, July 6th. Finally, UBS Group set a $150.00 target price on shares of Guardant Health in a research report on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $183.78.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.